Vaccinex, Inc. (VCNX): Price and Financial Metrics
Vaccinex, Inc. (VCNX)
Today's Latest Price: $4.82 USD
Updated Nov 11 6:55pm
Add VCNX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VCNX Stock Summary
- Vaccinex Inc's stock had its IPO on August 9, 2018, making it an older stock than merely 0.84% of US equities in our set.
- For VCNX, its debt to operating expenses ratio is greater than that reported by only 0.39% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Vaccinex Inc's debt growth rate surpasses only 0% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Vaccinex Inc, a group of peers worth examining would be ALPN, FIXX, TLC, ARDS, and SNDX.
- VCNX's SEC filings can be seen here. And to visit Vaccinex Inc's official web site, go to www.vaccinex.com.
VCNX Stock Price Chart More Charts
VCNX Price/Volume Stats
| Current price | $4.82 |
| Prev. close | $5.45 |
| Day low | $4.82 |
| Day high | $5.49 |
| 50-day MA | $6.05 |
| 200-day MA | $5.56 |
| 52-week high | $8.49 |
| 52-week low | $3.32 |
| Volume | 4,600 |
| Avg. volume | 8,696 |
| Dividend yield | N/A |
| Market Cap | 71.64M |
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Top Stories View All
Best & Worst Performing Stock Industries for November 11, 2019
Best & Worst Performing Small Cap Stocks for November 11, 2019
Best & Worst Performing Mid Cap Stocks for November 11, 2019
Best & Worst Performing Large Cap Stocks for November 11, 2019
Best & Worst Performing Mega Cap Stocks for November 11, 2019
View All Top Stories
Loading social stream, please wait...